Adenosine thiamine triphosphate (AThTP) inhibits poly(ADP-ribose) polymerase-1 (PARP-1) activity

Journal of Nutritional Science and Vitaminology

Volumn 57, Issue 2, 2011, Pages 192-196

  Tanaka, Takao ^a   Yamamoto, Daisuke ^a   Sato, Takaji ^a   Tanaka, Sunao ^b   Usui, Kazuya ^a   Miki, Manabe ^a   Aoki, Yui ^a   Iwashima, Yasuki ^a   Saito, Yoshihiro ^a   Mino, Yoshiki ^a   Deguchi, Hirofumi ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenosine thiamine triphosphate; Poly(ADP ribose) polymerase 1

Indexed keywords

ADENOSINE THIAMINE TRIPHOSPHATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; THIAMINE TRIPHOSPHATE; UNCLASSIFIED DRUG;

BINDING SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPOTHESIS; NOTE; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SYNTHESIS;

ADENOSINE TRIPHOSPHATE; ANIMALS; BINDING SITES; DIABETES COMPLICATIONS; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NAD; POLY(ADP-RIBOSE) POLYMERASES; RECOMBINANT PROTEINS; THIAMINE; THIAMINE TRIPHOSPHATE;

MAMMALIA;

EID: 79959746316     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.57.192     Document Type: Note

References (25)

1. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. 2003. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52: 2110-2120.
2. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
3. Hammes H P, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neu-maier M, Bergfeld R, Giardino I, Brownlee M. 2003. Benfotiamine blocks three major pathways of hypergly-cemic damage and prevents experimental diabetic reti-nopathy. Nat Med 9: 294-299.
4. Kohda Y, Shirakawa H, Yamane K, Otsuka K, Kono T, Terasaki F, Tanaka T. 2008. Prevention of incipient diabetic cardiomyopathy by high-dose thiamine. J Toxicol Sci 33: 459-472.
5. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. 2003. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52: 1-8.
6. Kiss L, Szabó C. 2005. The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cyto-toxicity. Mem Inst Oswaldo Cruz 100: 29-37.
7. Pacher P, Szabó C. 2005. Role of poly(ADP-ribose) poly-merase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal 7: 1568-1580.
8. Szabó C. 2005. Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacol Res 52: 60-71.
9. Bettendorff L, Wirtzfeld B, Makarchikov A, Mazzucchelli G, Frédérich M, Gigliobianco T, Gangolf M, De Pauw E, Angenot L, Wins P. 2007. Discovery of a natural thia-mine adenine nucleotide. Nat Chem Biol 3: 211-212.
10. Frédérich M, Delvaux D, Gigliobianco T, Gangolf M, Dive G, Mazzucchelli G, Elias B, De Pauw E, Angenot L, Wins P, Bettendorff L. 2009. Thiaminylated adenine nucle-otides. FEBS J 276: 3256-3268.
11. Bettendorff L. 1994. Thiamine in excitable tissues: reflections on a non-cofactor role. Metab Brain Dis 9: 183-209.
12. Singleton CK, Martin PR. 2001. Molecular mechanisms of thiamine utilization. Curr Mol Med 1: 197-207.
13. Bâ A. 2008. Metabolic and structural role of thiamine in nervous tissues. Cell Mol Neurobiol 28: 923-931.
14. Bettendorff L, Wins P. 2009. Thiamin diphosphate in biological chemistry: new aspects of thiamin metabolism, especially triphosphate derivatives acting other than as cofactors. FEBS J 276: 2917-2925.
15. Ruf A, Rolli V, de Murcia G, Schulz GE. 1998. The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. J Mol Biol 278: 57-65.
16. Karlberg T, Hammarström M, Schütz P, Svensson L, Schüler H. 2010. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry 49: 1056-1058.
17. Halgren TA. 1996. Merck molecular force field. I-V. J Comput Chem 17: 490-641.
18. Berendsen HJC, Postma JPM, Van Gunsteren WF, DiNola A, Haak JR. 1984. Molecular dynamics with coupling to an external bath. J Chem Phys 81: 3684-3690.
19. Bond SD, Leimkuhler BJ, Laird BB. 1999. The Nosé-Poincaré method for constant temperature molecular dynamics. J Comp Phys 151: 114-134.
20. + binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 37: 3893-3900.
21. Matsumoto K, Kondo K, Ota T, Kawashima A, Kitamura K, Ishida T 2006. Binding mode of novel 1-substituted quinazoline derivatives to poly(ADP-ribose) polymerase-catalytic domain, revealed by X-ray crystal structure analysis of complexes. Biochim Biophys Acta 1764: 913-919.
22. Miyashiro J, Woods K W, Park CH, Liu X, Shi Y, Johnson EF, Bouska JJ, Olson AM. 2009. Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Bioorg Med Chem Lett 19: 4050-4054.
23. Makarchikov AF, Brans A, Bettendorff L. 2007. Thia-mine diphosphate adenylyl transferase from E. coli: functional characterization of the enzyme synthesizing adenosine thiamine triphosphate. BMC Biochem 8: 17.
24. Tanaka T, Kono T, Terasaki F, Yasui K, Soyama A, Otsuka K, Fujita S, Yamane K, Manabe M, Usui K, Kohda Y. 2010. Thiamine prevents obesity and obesity-associated metabolic disorders in OLETF rats. J Nutr Sci Vitaminol 56: 335-346.
25. Tanaka T, Sohmiya K, Kono T, Terasaki F, Horie R, Ohkaru Y, Muramatsu M, Takai S, Miyazaki M, Kitaura, Y. 2007. Thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR: uncoupling of glucose oxidation from cellular entry accompanied with enhanced protein O-GlcNAcylation in CD36 deficiency. Mol Cell Biochem 299: 23-35.